rethinkPeptides Search
Menu
Home / Research library
Study breakdown

Danuglipron Metabolites Characterized: Understanding How Oral GLP-1 Small Molecules Are Processed

RPEP-153652026Jaiswal, Anupam; Biradar, Rushikesh; Deshmukh, Vaibhav; Deshpande, Rashmi; Nandi, Sukhendu
evidence
The takeaway

Comprehensive metabolite profiling of danuglipron (a small-molecule oral GLP-1 agonist) in vitro and in vivo identified major metabolic pathways and metabolites, informing safety assessment and drug development.

New chemistry, new metabolism

Unlike peptide GLP-1 drugs, small-molecule danuglipron is metabolized through hepatic pathways requiring comprehensive characterization

What the researchers found

Comprehensive identification of danuglipron metabolites in vitro and in vivo, characterizing major metabolic pathways for this novel small-molecule oral GLP-1R agonist.

Why it matters

Small-molecule GLP-1 drugs are new — understanding their metabolism is essential for predicting drug interactions and ensuring safety.

How the study worked

In vitro (liver microsomes, hepatocytes) and in vivo metabolite identification using mass spectrometry-based approaches.

What this study cannot tell us

Investigational drug. Metabolite identification may not capture all low-abundance species.

How to read the evidence

Thorough preclinical metabolite identification study supporting regulatory submission.

When this study was published

Published in 2025.

The bigger picture

As GLP-1 therapy evolves from peptides to small molecules, understanding their distinct metabolism is crucial for safe development.

Questions still open

  • Do danuglipron metabolites retain GLP-1 receptor activity?
  • Are there clinically significant drug interactions predicted?
  • How does metabolism differ from orforglipron (another small-molecule GLP-1)?

Common questions

What is danuglipron?
A small-molecule oral GLP-1 drug (not a peptide like semaglutide). Understanding how the body processes it is essential because it is metabolized differently from peptide drugs.
Why does metabolism matter for new drugs?
How the body breaks down a drug affects its safety, effectiveness, and potential interactions with other medications. This study maps those pathways for danuglipron.

Read the original research

Comprehensive identification and characterization of in vitro and in vivo metabolites of the novel GLP-1 receptor agonist danuglipron using UHPLC-QToF-MS/MS.

Journal of pharmaceutical and biomedical analysis, 267, 117128

View on PubMed ↗Publisher’s paper ↗

Citation

Jaiswal, Anupam; Biradar, Rushikesh; Deshmukh, Vaibhav; Deshpande, Rashmi; Nandi, Sukhendu. (2026). Comprehensive identification and characterization of in vitro and in vivo metabolites of the novel GLP-1 receptor agonist danuglipron using UHPLC-QToF-MS/MS.. Journal of pharmaceutical and biomedical analysis, 267, 117128. https://doi.org/10.1016/j.jpba.2025.117128